Mendel Money Management Acquires Shares of 48,700 Certara, Inc. (NASDAQ:CERT)

Mendel Money Management bought a new position in shares of Certara, Inc. (NASDAQ:CERT) in the fourth quarter, HoldingsChannel reports. The institutional investor bought 48,700 shares of the company’s stock, valued at approximately $519,000.

Several other hedge funds have also added to or reduced their stakes in the company. Kopion Asset Management LLC boosted its stake in shares of Certara by 46.0% in the 4th quarter. Kopion Asset Management LLC now owns 555,643 shares of the company’s stock valued at $5,918,000 after purchasing an additional 175,005 shares during the last quarter. Principal Financial Group Inc. grew its holdings in Certara by 3.1% during the 4th quarter. Principal Financial Group Inc. now owns 531,445 shares of the company’s stock worth $5,660,000 after acquiring an additional 15,739 shares during the period. Vontobel Holding Ltd. bought a new stake in shares of Certara during the 4th quarter valued at $1,295,000. Barclays PLC lifted its stake in shares of Certara by 198.3% in the 3rd quarter. Barclays PLC now owns 70,525 shares of the company’s stock valued at $825,000 after purchasing an additional 46,880 shares during the period. Finally, Proficio Capital Partners LLC acquired a new stake in shares of Certara during the fourth quarter worth $148,000. Institutional investors own 73.96% of the company’s stock.

Certara Stock Performance

Shares of Certara stock opened at $10.32 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of -51.60, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60. The stock’s 50-day moving average is $12.54 and its 200-day moving average is $11.47. Certara, Inc. has a one year low of $9.41 and a one year high of $19.18.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on CERT shares. Stephens restated an “overweight” rating and set a $17.00 target price on shares of Certara in a research report on Thursday, February 27th. Barclays upped their target price on shares of Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. TD Cowen began coverage on shares of Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 price target on the stock. Finally, William Blair reissued a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Certara has a consensus rating of “Moderate Buy” and an average price target of $15.83.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.